相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The Neutrophil
Garth Lawrence Burn et al.
IMMUNITY (2021)
Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond
Thomas Jung et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
Yating Zhao et al.
FRONTIERS IN PHARMACOLOGY (2021)
PD-L1(+)NEUT, Foxp3(+)Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma
Lin Zhou et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)
Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer
Louis Boafo Kwantwi et al.
BIOENGINEERED (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
On the origin of low-density neutrophils
Marwan Hassani et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16highCD62Ldim immunosuppressive subset
Enrique Podaza et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
Ik Sun Kim et al.
NATURE CELL BIOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Julia Kargl et al.
JCI INSIGHT (2019)
Roles of neutrophils in cancer growth and progression
Maria Rosaria Galdiero et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Jeffrey E. Gershenwald et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Potential involvement of neutrophils in human thyroid cancer
Maria Rosaria Galdiero et al.
PLOS ONE (2018)
Cancer-associated fibroblasts induce PDL1+neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma
Yusheng Cheng et al.
CELL DEATH & DISEASE (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway
Ting-ting Wang et al.
GUT (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
GM-CSF and IL-3 Modulate Human Monocyte TNF-α Production and Renewal in In Vitro Models of Trained Immunity
Francesco Borriello et al.
FRONTIERS IN IMMUNOLOGY (2017)
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Michael R. Cassidy et al.
EBIOMEDICINE (2017)
Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies
Zubing Mei et al.
CANCER TREATMENT REVIEWS (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Human neutrophils in the saga of cellular heterogeneity: insights and open questions
Patrizia Scapini et al.
IMMUNOLOGICAL REVIEWS (2016)
Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer
Maria Rosaria Galdiero et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
What does PD-L1 positive or negative mean?
Antoni Ribas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
P. F. Ferrucci et al.
BRITISH JOURNAL OF CANCER (2015)
Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
Gaixia He et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Distinct Functions of Neutrophil in Cancer and Its Regulation
Zvi Granot et al.
MEDIATORS OF INFLAMMATION (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer
Jitka Y. Sagiv et al.
CELL REPORTS (2015)
Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway
Nathan L. Bowers et al.
PLOS PATHOGENS (2014)
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Jahan S. Khalili et al.
CLINICAL CANCER RESEARCH (2012)
A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1
Janesh Pillay et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies
L Bingle et al.
JOURNAL OF PATHOLOGY (2002)
A practical approach to multicolor flow cytometry for immunophenotyping
N Baumgarth et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
分享论文
